Literature DB >> 9045682

Jak1 expression is required for mediating interleukin-4-induced tyrosine phosphorylation of insulin receptor substrate and Stat6 signaling molecules.

X H Chen1, B K Patel, L M Wang, M Frankel, N Ellmore, R A Flavell, W J LaRochelle, J H Pierce.   

Abstract

The Jak1, Jak2, Jak3, and Fes tyrosine kinases have been demonstrated to undergo tyrosine phosphorylation in response to interleukin (IL)-4 stimulation in different cell systems. However, it is not clear which, if any, of these kinases are responsible for initiating IL-4-induced tyrosine phosphorylation of intracellular substrates in vivo. In the present study, we have utilized a mutant Jak1-deficient HeLa cell line, E1C3, and its parental Jak1-expressing counterpart, 1D4, to analyze the role of Jak1 in mediating IL-4-induced tyrosine phosphorylation events. IL-4 treatment rapidly induced tyrosine phosphorylation of insulin receptor substrate (IRS)-1 and IRS-2 in 1D4 but not in E1C3 cells. IL-4-mediated tyrosine phosphorylation of Stat6 was pronounced in 1D4 cells, while no IL-4-induced Stat6 phosphorylation was detected in E1C3 cells. IL-4 also induced Stat6 DNA binding activity from lysates of 1D4 but not E1C3 cells utilizing a radiolabeled immunoglobulin heavy chain germline epsilon promotor sequence (Iepsilon) in an electrophoretic mobility shift assay. Reconstitution of Jak1 expression in E1C3 cells restored the ability of IL-4 to induce IRS and Stat6 tyrosine phosphorylation. These results provide evidence that Jak1 expression is required for mediating tyrosine phosphorylation and activation of crucial molecules involved in IL-4 signal transduction.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9045682     DOI: 10.1074/jbc.272.10.6556

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  11 in total

Review 1.  IL-4: an important cytokine in determining the fate of T cells.

Authors:  J L Silva-Filho; C Caruso-Neves; A A S Pinheiro
Journal:  Biophys Rev       Date:  2014-01-09

Review 2.  Genetics of eosinophilic esophagitis.

Authors:  L C Kottyan; M E Rothenberg
Journal:  Mucosal Immunol       Date:  2017-02-22       Impact factor: 7.313

3.  Interferons inhibit activation of STAT6 by interleukin 4 in human monocytes by inducing SOCS-1 gene expression.

Authors:  H L Dickensheets; C Venkataraman; U Schindler; R P Donnelly
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-14       Impact factor: 11.205

Review 4.  Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway.

Authors:  P C Heinrich; I Behrmann; G Müller-Newen; F Schaper; L Graeve
Journal:  Biochem J       Date:  1998-09-01       Impact factor: 3.857

5.  Cutting edge: SOCS-1 is a potent inhibitor of IL-4 signal transduction.

Authors:  J A Losman; X P Chen; D Hilton; P Rothman
Journal:  J Immunol       Date:  1999-04-01       Impact factor: 5.422

6.  Transient inhibition of interleukin 4 signaling by T cell receptor ligation.

Authors:  J Zhu; H Huang; L Guo; T Stonehouse; C J Watson; J Hu-Li; W E Paul
Journal:  J Exp Med       Date:  2000-10-16       Impact factor: 14.307

7.  Impaired interleukin 4 signaling in T helper type 1 cells.

Authors:  H Huang; W E Paul
Journal:  J Exp Med       Date:  1998-04-20       Impact factor: 14.307

Review 8.  Fueling Cancer Immunotherapy With Common Gamma Chain Cytokines.

Authors:  Connor J Dwyer; Hannah M Knochelmann; Aubrey S Smith; Megan M Wyatt; Guillermo O Rangel Rivera; Dimitrios C Arhontoulis; Eric Bartee; Zihai Li; Mark P Rubinstein; Chrystal M Paulos
Journal:  Front Immunol       Date:  2019-02-20       Impact factor: 7.561

Review 9.  IL-4 and IL-13 Receptor Signaling From 4PS to Insulin Receptor Substrate 2: There and Back Again, a Historical View.

Authors:  Achsah D Keegan; Jose Zamorano; Aleksander Keselman; Nicola M Heller
Journal:  Front Immunol       Date:  2018-05-15       Impact factor: 7.561

Review 10.  Aspirin Actions in Treatment of NSAID-Exacerbated Respiratory Disease.

Authors:  Esha Sehanobish; Mohammad Asad; Mali Barbi; Steven A Porcelli; Elina Jerschow
Journal:  Front Immunol       Date:  2021-06-25       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.